chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Muscle, joint and nerve pain; Muscle, joint and nerve pain; Muscle, joint and nerve pain; fatigue; Fever; This is a spontaneous report from a contactable other hcp. This HCP (Patient) reported that a 36-year-old non-pregnant female patient received bnt162b2 (BNT162B2, Formulation: Solution for injection, Batch/Lot number: EM9810), dose 2 via an unspecified route of administration, administered in Arm Left on 05Feb2021 09:00 as DOSE 2, SINGLE for covid-19 immunisation. The patient had no medical history. Concomitant medication(s) included escitalopram oxalate (LEXAPRO) 20mg/day. Patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unknown route of administration on 15Jan2021 at 05:00 PM in Arm Left (Batch/Lot number : EL3248) as 1ST DOSE, SINGLE for covid-19 immunisation. Patient had no known allergies. On 05Feb2021 07:00, the patient experienced muscle, joint and nerve pain; fatigue and fever. The patient underwent lab tests and procedures which included pyrexia: 101-103 f on 05Feb2021 Fever starting -15 hrs after shot lasting -6 hours, ranging 101-103 F. Patient was received self treatment and OTC medications for events. It was reported that With 2nd shot, Fatigue starting 8 hours after shot lasting for 2 days, not improved with rest, Fever starting 15 hrs. After shot lasting 6 hours, ranging 101-103 F, resolved without medications. Muscle, joint and nerve pain starting 12 hours after shot, muscle and joint pain resolved within 30-60 min of taking 1 tablet naproxen 220 mg, nerve pain (characterized by pressure perceived as burning/tingling pain) resolved 12-15 hours after start but did not improve with rest or OTC painkillers. The clinical outcome of event fatigue was not recovered; while others were recovered.  Follow-up attempts are completed. No further information is expected.
Information has been received from a health care professional concerning a 34 year old female who was vaccinated with a dose of Fluzone IM in the left deltoid. The date of vaccination was not reported. The lot # is U0877AA and the expiration date is 6/30/03. The patient became pale and nauseous within 2 minutes post vaccination. She also experienced vomiting (small amount), and numbness in both hands. Her lung sounds were clear and blood pressure was 140/90. She was administered with oxygen through a facemask and with Benadryl 50mg IM. She recovered two hours later.
Patient received second dose after 21 days/almost 22 days after the first dose/Second dose 48 hours before the recommended time frame; This spontaneous case was reported by a nurse and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received second dose after 21 days/almost 22 days after the first dose/Second dose 48 hours before the recommended time frame) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received second dose after 21 days/almost 22 days after the first dose/Second dose 48 hours before the recommended time frame). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received second dose after 21 days/almost 22 days after the first dose/Second dose 48 hours before the recommended time frame) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant use were reported No Treatment were reported
Slight reaction after first vaccine-dry skin, slight rash Terrible reaction following second vaccine.  Severe skin rash, racing heart, high blood pressure, shortness of breath Diagnosed as a hypersensitivity reaction Placed on  steroid taper 40 mg-4 days, 30 mg-4 days 20 mg- 4 days the severe rash returned and worsened Went to urgent care steroids increased
Day 1 (9/3/2021) - arm became really hot and was extremely painful Day 2  (9/4/2021)- hot, splotchy rash on injection arm; lasted 12 hours                 painful arm, difficult to move Day 3  (9/5/2021) -   multiple hot, splotchy rashes on other arm; 3 rashes in different spots; each lasted about 4 hours                  painful arm, difficult to move Day 6-11  (9/8/2021- 9/13/2021)- pain and tightness in breast implant on right side; this is my cancer and radiation side Day 9  (9/11/2021)  large red welt and rash showed up on vaccine side around injection site Day 11  (9/13/2021)- rash and itchiness around my breast implant on my right side at the top of the impant Day 12 (9/14/2021) - flashing lines of light in my left eye, started about 6:00pm and continued until around 9:30pm
Minor pain in their shoulder, (same side of the injection); This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (Minor pain in their shoulder, (same side of the injection)) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Glaucoma. Concomitant products included NAPHAZOLINE HYDROCHLORIDE (EYE DROPS [NAPHAZOLINE HYDROCHLORIDE]) for Glaucoma.    On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ARTHRALGIA (Minor pain in their shoulder, (same side of the injection)). At the time of the report, ARTHRALGIA (Minor pain in their shoulder, (same side of the injection)) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment medications were not provided by reporter.
History of headache, muscle ache joint pain for last 2 days after getting the 2 shots with fever 101. Given Motrin and benadryl.
fever and left leg swollen from injection site to knee and was hot to touch.  went to doctor office. continue advil for fever and apply warm cloth to swollen area.  this am fever gone but swelling still present.
Depression has worsened since 2nd vaccine; Not eating as much/Noeating very li; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of DEPRESSION (Depression has worsened since 2nd vaccine) and EATING DISORDER (Not eating as much/Noeating very li) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DEPRESSION (Depression has worsened since 2nd vaccine) and EATING DISORDER (Not eating as much/Noeating very li). At the time of the report, DEPRESSION (Depression has worsened since 2nd vaccine) and EATING DISORDER (Not eating as much/Noeating very li) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant and treatment medications were provided   Reporter did not allow further contact
no other AE; Caller is a pharmacist who reports a temperature excursion involving VARIVAX. He does not know whether any doses were administered following the temperature excursion.; This spontaneous report was received from a pharmacist referring to a patient of unknown age and gender. The patient's pertinent medical history, concomitant medications, concurrent conditions, and previous drug reactions or allergies were not reported.  On an unknown date, varicella virus vaccine live (oka/merck) (VARIVAX) (lot #W011623, expiration date: 06-APR-2024) underwent a temperature excursion at minus 10 degrees Celsius for 1400 hours. There was no previous temperature excursion.  On 11-AUG-2022, the patient was vaccinated with the improperly stored varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneous injection (strength, dose, and route of administration were not provided; lot #W011623, expiration date: 06-APR-2024), administered for prophylaxis (Product storage error). There was no other AE (No adverse event).  This is one of 13 reports received from the same reporter.; Sender's Comments:  US-009507513-2209USA010264: US-009507513-2209USA010265: US-009507513-2209USA010266: US-009507513-2209USA010267: US-009507513-2209USA010268: US-009507513-2209USA005873: US-009507513-2209USA010270: US-009507513-2209USA010271: US-009507513-2209USA010272: US-009507513-2209USA010273: US-009507513-2209USA010274: US-009507513-2209USA010275:
patient with a contraindication receiving a live virus vaccine (vaccine error). No actual AE has occurred at this time (<24 hours after error)
A report was received from a health care professional on 12/16/03 concerning a group of 5 vaccinees aged less than 4 years of age and of unknown gender who were inadvertently administered Fluvirin on an unknown date. On an unknown date, a group of 5 vaccinees aged less than 4 years of age and of unknown gender were inadvertently administered Fluvirin. No adverse events have occurred as a result of this at the time of this report. There was insufficient information to determine the reporter's causality assessment. Update 3/26/04: A follow up report was received from a health care professional indicating that a 1 year old male vaccinee experienced symptoms of fever and cough 2 months after inadvertently receiving 0.25ml Fluvirin on 11/24/03. The vaccinee recovered after approximately 7 days. On an unspecified date, the vaccinee tested negative for influenza A and influenza B. Follow up pending.
1st dose of Moderna. 1st dose, 0-4hrs after injection; Fatigue, metallic taste in mouth, increased thirst and urination, dizzy, chills, achy, headache, low grade fever. 24 - 48hrs after injection; increased resting heart rate; 95-96 bpm (normally in the 60's), fatigue, chills and low grade fever.
Then armpit swelling, lymph nodes were swollen; Then armpit swelling, lymph nodes were swollen; backache and arm swelling/tenderness; Fever; chills; nausea; backache and swelling/tenderness; backache and swelling/tenderness; This is a spontaneous report received from a contactable consumer (patient). A 33-years-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution injection, Lot Number: EN6200), dose 2 via intramuscular, administered in arm right on 18Feb2021 at 15:30 (at the age of 33-years-old) as single for COVID-19 immunisation. Medical history included caesarean section in 04Aug2017 for birth of daughter, caesarean section from 03Feb2020 for date birth of daughter and anxiety. Concomitant medications included ethinylestradiol, norgestimate (ESTARYLLA) for birth conrtrol, zinc taken for immune enhancement therapy from Aug2020 and ongoing, and escitalopram oxalate (LEXAPRO) taken for anxiety from an unspecified start date and ongoing. The patient previously received the first dose of bnt162b2 (Lot Number: EL1283), intramuscular, administered in arm right on 23Jan2021 at 11.00 as single for COVID-19 immunisation. Patient did not receive any prior vaccination within 4 weeks. On 19Feb2021 at 03:00, within 14 hours of vaccination, the patient experienced fever, chills, nausea, backache and swelling/ tenderness. After 24 hours of these symptoms, it stopped. On 20Feb2021, she experienced armpit swelling and lymph nodes were swollen for 3 days after other symptoms stopped. The patient did not receive treatment for the events. The outcome of all the events was resolved.  No follow-up attempts are needed. No further information is expected.
9MAY91 inc temp, sore throat, macropapular rash, 10MAY91 inc skin rash, malaise;
dose administered greater than 24 hours at room temperature/ dose administered after more then 12 hours from first puncture; dose administered greater than 24 hours at room temperature/ dose administered after more then 12 hours from first puncture; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (dose administered greater than 24 hours at room temperature/ dose administered after more then 12 hours from first puncture) and PRODUCT STORAGE ERROR (dose administered greater than 24 hours at room temperature/ dose administered after more then 12 hours from first puncture) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 060H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Feb-2022 at 2:00 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Feb-2022 at 2:00 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (dose administered greater than 24 hours at room temperature/ dose administered after more then 12 hours from first puncture) and PRODUCT STORAGE ERROR (dose administered greater than 24 hours at room temperature/ dose administered after more then 12 hours from first puncture). At the time of the report, EXPIRED PRODUCT ADMINISTERED (dose administered greater than 24 hours at room temperature/ dose administered after more then 12 hours from first puncture) and PRODUCT STORAGE ERROR (dose administered greater than 24 hours at room temperature/ dose administered after more then 12 hours from first puncture) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   A vial was removed from freezer and transferred to refrigerator on 08-Feb-2022. It was then removed from the refrigerator and first punctured on 16-Feb at 0930hours and remained at room temperature thereafter. A dose was administered on 17-Feb at 1400hours.   No concomitant medications were reported.  No treatment information was reported.
This spontaneous report was received from a physician refers to a 63 year old female patient. No medical history was reported. On 15-MAR-2013, the patient was vaccinated with a dose of ZOSTAVAX (lot #, route, dose not reported). Concomitant therapies included ACTONEL. On an unknown date in March 2013, the patient had a raised red rash at the site of the injection site. The patient's rash was 3 inches in circumference, erythematous, warm and pruritic. Physician was recommending hydrocortisone cream. No treatment was received for the events. No medical attention was sought by the patient. The outcome of rash which was 3 inches in circumference, erythematous, warm and pruritic was unknown. The relatedness of the events with ZOSTAVAX was unknown. Additional information is not expected.
I had H eart Palpations and Chest Pains  for four months, had to seek urgent care treatment. I went through numerous test such as 24hr Holter Monitoring, Cardiac Stress Test, Cardiac Echo. PVC's were detected in the 24 hr Holter monitoring .
his arm is fairly sore; This is a spontaneous report from a contactable consumer. This consumer reported for a 67 Years-Old male patient (husband). A 67-years-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection), dose 2 via an unspecified route of administration on 15Feb2021 (Batch/Lot number was not reported) as DOSE 2, SINGLE for covid-19 immunisation.  The patient medical history and concomitant medications were not reported.  on an unspecified date the who received the second dose of the Pfizer vaccine yesterday and his arm is fairly sore. Can he take Motrin. Outcome of the event was unknown.  Information on the lot/ batch number has been requested.  Follow-up attempts are completed. No further information is expected.
Pt got her second Covid Vaccine. She then sat and waited for 15 minutes at the Pharmacy. She got up and went back to work, Then we got a call from the back that she wasn't feeling well. She said she was feeling dizzy and nauseous. She then said was going home to rest.
Tennis ball size redness / over the injection site; There is also a lump; There is also / sore / soreness at injection site; There is also / warm to the touch; This case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On 22nd June 2021, the patient received the 1st dose of Shingrix. In June 2021, less than a day after receiving Shingrix, the patient experienced injection site erythema, injection site lump, injection site pain and injection site warmth. On an unknown date, the outcome of the injection site erythema, injection site lump, injection site pain and injection site warmth were not recovered/not resolved.   It was unknown if the reporter considered the injection site erythema, injection site lump, injection site pain and injection site warmth to be related to Shingrix.  Additional details were provided as follows: This case was reported by the patient himself/ herself. The age at vaccination was not reported. The patient received the first dose of Shingrix 3 days ago and experienced redness about the size of a tennis ball over the injection site. There was also a lump that was sore and warm to the touch. The reactions had not recovered till the time of vaccination. The reporter would continue to watch site and contact physician if it doesn't clear up in a few more days.
I started running a fever couple a hours,dizziness, nausea that lasted to around 12:00 pm. I missed a day of work dint feel safe driving.
Initial report received from a healthcare professional on 02 April 2013. A patient whose age, gender and concomitant medications were not reported, had received a dose of DTaP vaccine (dose number, lot number, route and anatomical site of vaccination - not reported) on an unspecified date. The patient's pre-existing physician diagnosed allergies, birth defects, and illness at time of vaccination were as unknown. The patient developed a rash on an unspecified date. The reporter declined to provide information to complete the form, stated that it was a Sanofi Pasteur product and the vaccine were not given by their office. Corrective treatment and laboratory investigations were not reported. At the time of this report, the outcome of the event was reported as unknown. List of documents held by sender: none.
Pt reports having generalized urticaria.  Was not seen by medical provider when this started.
No additional symptoms were reported/No additional AE/PQC; inadvertent exposure to MMR-II during vaccine preparation for a patient; Nurse stated that during preparation of the vaccine, she accidently splashed a small amount of MMR-II into her own eye.; This spontaneous report has been received from a 33-year-old female nurse, referring to herself. Information regarding current conditions, pertinent medical history, previous drug reactions or allergies and concomitant medications were not provided.  On 19-OCT-2023, the nurse experienced an inadvertent exposure to measles, mumps, and rubella recombinant Human albumin (rHA) (Wistar RA 27-3) virus vaccine, live (M-M-R II) subcutaneous injection (dose, route of administration and anatomical location of vaccination were not provided; lot number W035197 has been verified to be valid, expiration date 24-MAY-2024) during vaccine preparation for a patient as prophylaxis (accidental exposure to product); she accidently splashed a small amount of the vaccine into her own eye (occupational exposure to product). No additional symptoms or events were reported. The patient that was scheduled for the measles, mumps, and rubella recombinant Human albumin (rHA) (Wistar RA 27-3) virus vaccine, live (M-M-R II) administration was still able to receive a full dose.
muscle pain in his shoulder, upper quarter or his chest and back sometimes quite large area; muscle pain in his shoulder, upper quarter or his chest and back sometimes quite large area; muscle pain in his shoulder, upper quarter or his chest and back sometimes quite large area; not able to sleep on his left side; This is a spontaneous report from a contactable consumer (patient) received via medical information team. A male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot Number: EL9266), via an unspecified route of administration in left arm on 25Feb2021 as dose 1, single for COVID-19 immunization. Medical history included ongoing pacemaker use. The patient's concomitant medications were not reported. The patient experienced muscle pain in his shoulder, upper quarter or his chest and back sometimes quite large area and not able to sleep on his left side on 26Feb2021. It was reported that first day patient had no problem, second day in the evening developed a muscle pain in shoulder, on chest and back sometimes quite large area, and can't sleep on his left side. It continued right up until those days although it had been subsiding for the past 6 days but still present. Patient asked should he get the next vaccine and if yes then should he get it in his right arm instead of left and can expect same results. Outcome of events was resolving.
Pt received MMR vaccine. Following vaccination, patient's niece reports that patient is late for menses. She denied pregnancy to nurse. UPT done and it was positive.
This is a spontaneous report from a contactable consumer who reported for herself. A female patient of an unspecified age received TRUMENBA on an unspecified date at single dose for immunisation.The patient medical history and concomitant medications were not reported. Meningococcal group b rlp2086 was the only shot given at that time. On an unspecified date, 24 hours after the injection, the patient experienced hot and cold sweats, headache, nausea and fatigue. Events were non-serious with outcome of unknown.
Information has been received from a registered nurse regarding a patient of unknown age and gender. On 13-SEP-2011, the patient was administered with a dose of VARIVAX (Merck) (Lot # 0345AA expiry date unknown) (Route, dosing regimen and frequency unknown) which was exposed to a temperature excursion of up to -3 degrees Centigrade. No adverse events were reported. No product quality issue was reported. This is one of 121 reports received from the same source. Additional information has been requested.
Chicken pox, fever and blisters. Treated with Aveeno, Benadryl and fever control.
Resident developed hemoptysis, evaluated in ER at which time hemoptysis had resolved. Upon ER admission, resident had unresponsive episode with hypotension, IV fluids administered with resolution. Diagnostic work up unremarkable. Resident returned to facility with recommendations to discontinue ASA. No further symptoms noted